QRG Capital Management Inc. Raises Stock Position in Eli Lilly and Company $LLY

QRG Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 146,305 shares of the company’s stock after purchasing an additional 12,755 shares during the period. Eli Lilly and Company comprises approximately 1.3% of QRG Capital Management Inc.’s investment portfolio, making the stock its 12th biggest holding. QRG Capital Management Inc.’s holdings in Eli Lilly and Company were worth $175,483,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $30,000. Maseco LLP boosted its stake in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after buying an additional 28 shares during the last quarter. Aventus Investment Advisors Inc. grew its holdings in Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after acquiring an additional 27 shares during the period. Finally, Marshall & Sterling Wealth Advisors Inc. grew its holdings in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock traded down $16.45 during trading hours on Wednesday, hitting $1,153.69. 2,153,958 shares of the company’s stock were exchanged, compared to its average volume of 3,016,686. Eli Lilly and Company has a fifty-two week low of $712.05 and a fifty-two week high of $1,292.65. The firm has a market cap of $1.09 trillion, a P/E ratio of 38.71, a P/E/G ratio of 1.44 and a beta of 0.50. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a 50 day moving average of $1,176.84 and a two-hundred day moving average of $1,079.50.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter last year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 36.54 EPS for the current year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO Dave Ricks said Lilly is capturing about 70% of new senior GLP-1 patients following Medicare coverage expansion, while oral GLP-1 drug Foundayo accounts for roughly one-third of new oral-treatment starts. The comments reinforce Lilly’s commercial leadership and suggest that expanded insurance coverage could materially enlarge the addressable market. Lilly CEO discusses Medicare GLP-1 market share
• Positive Sentiment: Lilly broke ground on a $6.5 billion Houston manufacturing facility that will produce active ingredients for Foundayo and other medicines. The investment supports the company’s planned oral GLP-1 rollout, strengthens domestic supply, and is expected to create more than 600 jobs, although the benefits will take time to materialize. Lilly Houston manufacturing facility
• Positive Sentiment: Investors remain bullish on Lilly’s long-term growth. Home Depot co-founder Ken Langone said the shares could reach $2,000 within three to four years, reflecting confidence in the company’s obesity portfolio and broader pipeline. Ken Langone bullish on Lilly
• Neutral Sentiment: Lilly received full FDA approval for Inluriyo in combination with Verzenio for advanced ESR1-mutated breast cancer, adding support to its oncology franchise. The approval is strategically positive but likely less important to near-term valuation than the obesity business. Inluriyo FDA approval
• Negative Sentiment: Viking Therapeutics reported data indicating its VK2735 obesity drug preserved most weight loss with every-other-week or monthly dosing. The result drove strong interest in a potential competitor to Zepbound, raising concerns about future pricing, adherence, and market-share pressure for Lilly, although Viking still needs Phase 3 results and regulatory approval. Viking obesity drug maintenance data
• Negative Sentiment: Novo Nordisk’s CagriSema also produced favorable late-stage weight-loss data in a diabetes study, keeping competitive pressure high. Lilly’s $6.5 billion facility further increases near-term capital spending, which may temper enthusiasm despite strong long-term demand.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on LLY shares. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Sanford C. Bernstein increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a research report on Friday, August 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,419.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 6th. Finally, Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,305.25.

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 over the last 90 days. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.